# Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

> **NCT06841172** · PHASE3 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 132 (estimated)

## Conditions studied

- OligoProgressive Metastatic Disease
- Hepatocellular Carcinoma (HCC)
- Radiotherapy
- Systemic Therapy

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** Systemic therapy (Continuation of current first-line systemic therapy)
- **DRUG:** Systemic therapy (Early switch to second-line systemic therapy)

## Key facts

- **NCT ID:** NCT06841172
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-21
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06841172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06841172, "Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06841172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*